Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.

Advances in experimental medicine and biology - 1 Jan 2017

Okuma Hitomi Sumiyoshi, Yonemori Kan

Abstract excerpt

Breast cancer is the most common cancer in women worldwide. Treatment is chosen according to its hormone receptor status and human epidermal growth factor receptor 2 (HER2) status. Among the four main clinically set subtypes, hormone receptor-negative/HER2-negative subtype, also called triple-negative subtype (TNBC), is the most aggressive type with limited choices of therapy. However, recent research has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to PARP1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Share to Receptor, ErbB-2

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 29282689
DOI: 10.1007/978-981-10-6020-5_13

Genes

BRCA1
BRCA2
PARP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.PMID 29282689Read ↗

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and ResistanceSemantic proximity Read ↗

Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast CancerSemantic proximity Read ↗

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.Semantic proximity Read ↗

PARP inhibitors in breast cancer: BRCA and beyond.Semantic proximity Read ↗

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future PerspectivesSemantic proximity Read ↗

PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.Semantic proximity Read ↗

PARP Pioneers: Using BRCA1/2 Mutation-targeted Inhibition to Revolutionize Breast Cancer TreatmentSemantic proximity Read ↗

Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiencySemantic proximity Read ↗

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancersSemantic proximity Read ↗

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Semantic proximity Read ↗

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast CancerSemantic proximity Read ↗

Therapeutic advances and application of PARP inhibitors in breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.